Publications found:
73,128
Sort by:
Forensic Technology Market by Product (DNA Testing, Biometric Devices, Digital Forensics, and Ballistic Forensics), Service (DNA Profiling, Fingerprinting Analysis, Drug Analysis, and Firearm Analysis) - Global Opportunity Analysis and Industry Forecast, 2016-2023
US$ 5,370.00
... study provides an in-depth analysis of the global forensic technology market, with current trends and future estimations to elucidate ... contenders within the market framework. Forensic Technology Market Key Segments: By Product DNA Testing Biometric Devices Digital Forensics Ballistic Forensics Others By ...
June 2017
165 pages
BRCA 1 & 2 Mutation in Cancer Forecast in 18 Major Markets 2017-2027
US$ 6,150.00
... in individuals that carry the mutations. This report provides the current prevalent population for BRCA1 & BRCA2 mutations in cancer populations across 18 Major ... for various countries. Provide a level of understanding on the impact of the mutation on the prevalent population for specific cancer types. Gain an understanding ...
June 2017
136 pages
Global Acne Treatment Market: (2017-2021 Edition)
US$ 700.00
... Report The report entitled “Global Acne Treatment Market: (2017-2021 Edition)”, provides analysis of the global acne treatment market and its products, with detailed analysis of market size and growth in terms ... ) Executive Summary The global acne treatment market is growing rapidly over the years and is expected to increase further in the forecasted period (2017-2021). Global acne treatment is supported by a number of growth ...
June 2017
56 pages
CAR-T Disease Outlook [2017]
US$ 8,145.00
... -term durability and persistence of CAR-T therapies? Which diseases show most benefit to CAR-T treatment and why? Anti-CD19 CAR-T cells have been investigated ... lymphoma (NHL). What are the key opportunities facing CAR-T in each disease and which ones are KOLs most excited about? What ... to the KOLs? How can companies differentiate themselves to market CAR-T therapies? What do CAR-T manufacturers need to do in order to bring these therapies to market in a competitive ...
June 2017
-
Charting MSL Activity and Performance (2017)
US$ 5,145.00
... , internal communications and performance measurement from frontline MSL staff, look no further than Charting MSL Activity and Performance 2017. Key Benefits Understand which MSL activities are seen as being most important in the US and Europe Benchmark your own MSL ...
June 2017
-
Market Access Impact (EU5) [CLL]
US$ 5,145.00
... or changed? Market Access Impact: CLL (EU5) examines the dynamics of the CLL drug market in Europe. It specifically looks at how various market access barriers are impacting the 5 most popular CLL drugs from ... on Market Access issues Market Access Impact: CLL provides an up-to-date assessment of the issues affecting current prescribing patterns for CLL drugs. You’ll learn: How barriers affect market access Which CLL ...
June 2017
-
Market Access Impact (EU5) [Growth Hormone Deficiency]
US$ 5,145.00
... bigger problem Market barriers affect nearly 25% of growth hormone prescriptions in the EU5 countries. Most brands lose market share because of ... Market Access Barriers Market Access Impact: GHD (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access What ...
June 2017
-
Market Access Impact (EU5) [Haemophilia A]
US$ 5,145.00
... 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Haemophilia A (EU5). Based on a survey ... alfa; Pfizer) Exploring Market Access Barriers Market Access Impact: Haemophilia A (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...
June 2017
-
Market Access Impact (US) [CLL]
US$ 5,145.00
... or changed? Market Access Impact: CLL (US) examines the dynamics of the CLL drug market in the US. It specifically looks at how various market access barriers are impacting the 6 most popular CLL drugs from ... on Market Access issues Market Access Impact: CLL provides an up-to-date assessment of the issues affecting current prescribing patterns for CLL drugs. You’ll learn: How barriers affect market access Which CLL ...
June 2017
-
Market Access Impact (US) [Growth Hormone Deficiency]
US$ 5,145.00
... than one thing Market barriers affect over 20% of growth hormone prescriptions in the US, and most brands lose market share because of ... Exploring Market Access Barriers Market Access Impact: GHD (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access What brands ...
June 2017
-
Market Access Impact (US) [Haemophilia A]
US$ 5,145.00
... 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Haemophilia A (US). Based on a survey ... alfa; Pfizer Exploring Market Access Barriers Market Access Impact: Haemophilia A (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...
June 2017
-
Medical Affairs in Orphan Drugs
US$ 695.00
... awareness considerably The role of medical affairs in orphan drug development and commercialisation Summary The medical affairs team tends to play a pivotal role in orphan drug R&D Medical affairs has a critical role in identifying ... in resources for medical affairs highlights its importance for orphan drugs A different approach to non-orphan indications is required The future for medical affairs in orphan drugs Summary Medical affairs will continue to play ...
June 2017
-
Medical Affairs Reputations (EU5) [MS]
US$ 6,175.00
... report to understand how well your medical affairs team is currently doing, and how they compare to the rest. Medical Affairs Reputations: MS EU5) features 10 leading MS drugs from ... (natalizumab; Biogen) A Competitive Assessment of Medical Affairs Teams Developed with the help of medical affairs specialists, this report compares 10 medical affairs teams and answers key questions ...
June 2017
-
Medical Affairs Reputations (US) [MS]
US$ 6,175.00
... report to understand how well your medical affairs team is currently doing, and how they compare to the rest. Medical Affairs Reputations: MS (US) features 11 leading MS drugs from ... ; AbbVie/Biogen) A Competitive Assessment of Medical Affairs Teams Developed with the help of medical affairs specialists, this report compares 10 medical affairs teams and answers key questions ...
June 2017
-
NASH: KOL Insight [2017]
US$ 8,795.00
... how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Nonalcoholic steatohepatitis (NASH). 6 US and 6 European KOLs give their insight on two off-label marketed products and 12 pipeline programmes. KOLs also provide ...
June 2017
-
NPS+ (EU5) [Melanoma]
US$ 2,575.00
... from competitors in FirstView’s NPS+ Melanoma 2017 (EU5). Building on the respected net promoter score (NPS), the report compares seven major melanoma drugs with easy ... and 9th, 2017. Explore Important Brand Loyalty Issues NPS+ Melanoma 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers ...
June 2017
-
NPS+ (US) [Melanoma]
US$ 2,575.00
... satisfaction score in FirstView’s NPS+ Melanoma 2017 (US). Building on the respected net promoter score (NPS), the report compares eight major melanoma drugs with easy ... 3rd and 9th, 2017. Explore Important Brand Loyalty Issues NPS+ Melanoma 2017 (US) explores key issues affecting brand loyalty for drug ...
June 2017
-
The United States Digital Medicine Market (2017-2021 Edition)
US$ 600.00
... report titled “The United States Digital Medicine Market (2017-2021 Edition)”, provides an in-depth analysis of the scenario of digital medicine market in the United States. The US digital medicine market has been analysed on the basis of value, segments and clinical trials sponsors. The report also provides the digital ...
June 2017
34 pages
Acute Respiratory Distress Syndrome (ARDS) Forecast in 11 Major Markets 2017-2027
US$ 6,150.00
Acute respiratory distress syndrome (ARDS) is an acute severe lung disease. It most often develops in those admitted to an intensive ... in protein-rich non-cardiogenic pulmonary oedema, refractory hypoxaemia and acute respiratory failure. This report provides the current prevalent population for ...
June 2017
42 pages
PD-L1 Overexpression in Solid Tumours Forecast in 18 Major Markets 2017-2027
US$ 6,150.00
PD-1 is a T-cell immune checkpoint that is involved in the dampening of autoimmunity in the peripheral effector phase of T-cell activation. This leads to a ‘tolerance’ of cells expressing PD-L1 (programmed death ligand-1). PD-L1 is expressed normally on a number of different cell types including; placenta, ...
June 2017
148 pages
AML [2017]: Bulletin #1
US$ 1,045.00
This update bulletin presents key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) market. Topics covered include ... enasidenib (AG-221) for the treatment of patients with relapsed/refractory AML with an isocitrate dehydrogenase 2 (IDH2) mutation. Business Questions How do KOLs ...
June 2017
-
CLL [2016]: Bulletin #3
US$ 1,045.00
... provide their candid insights on the sequencing of novel targeted therapies in CLL, availability of real-world data and the future of chemotherapies. Business ... KOLs require clinical studies to demonstrate the similarity of Truxima to rituximab in CLL? If so, what studies are required? How comfortable are KOLs in extrapolating ...
June 2017
-
Cystic Fibrosis [2017]: Bulletin #1
US$ 1,045.00
... presents key opinion leader (KOL) views on recent developments in the cystic fibrosis market. Topics covered include: Corbus Pharmaceuticals’s announcement of positive data ...
June 2017
-
HNSCC [2017]: Bulletin #1
US$ 1,045.00
... (HNSCC). Topics covered include: KOL views on the approval of Bristol Myers Squibb’s Opdivo (nivolumab) for the second-line treatment of HNSCC, in April 2017 ... cancers, including HNSCC. Business Questions In March 2017, the EU’s CHMP recommended approval of Bristol-Myers Squibb’s Opdivo for the treatment of HNSCC, but how ...
June 2017
-
Melanoma [2016]: Bulletin #2
US$ 1,045.00
... of its investigational intratumoral therapy, ImmunoPulse IL-12, with Keytruda (pembrolizumab) in metastatic melanoma patients who are not expected to respond to anti-PD-1 agents. Business ... NDA for binimetinib as monotherapy in NRAS melanoma the right one? Does binimetinib have a future in NRAS melanoma? Is there room for the market ...
June 2017
-
Multiple Sclerosis [2016]: Bulletin #2
US$ 1,045.00
... events that have the potential to impact the treatment landscape of multiple sclerosis (MS). Topics covered include expert opinions on: the FDA approval of Ocrevus ...
June 2017
-
NSCLC [2016]: Bulletin #3
US$ 1,045.00
... on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar ... in the first-line treatment of ALK-positive NSCLC? How is the second-line treatment of ALK-positive NSCLC likely to evolve in light of recent events ...
June 2017
-
Payer Insights: RA [2016]: Bulletin #2
US$ 1,045.00
... ’s Olumiant (baricitinib) gaining marketing authorisation in the EU. Business Questions How do payers intend to cover sarilumab? Will there be any restrictions? Is sarilumab likely ... over biosimilars of Humira? How are biosimilars of Remicade viewed by payers? Are payers surprised that baricitinib was declined approval in the US, but not ...
June 2017
-
Global Rett Syndrome Market: Industry Analysis & Outlook (2017-2025)
US$ 800.00
... are being developed, which are in their clinical phases. The global Rett syndrome market will grow over the years driven by increase in female ... like high cost of treatment and high R&D expenditure. The report “Global Rett Syndrome Market: Industry Analysis & Outlook (2017-2025)” analyzes the development of ...
May 2017
64 pages
North America Wound Care Biologics Market by Manufacturers, Countries, Type and Application, Forecast to 2022
US$ 4,480.00
... formulations, Biologic Skin Substitutes, xenografts and cell based biogens to promote wound healing. SCOPE OF THE REPORT: This report focuses on the Wound Care Biologics in North America market ... be divided into Acute Wounds Chronic Wounds Surgical Wounds There are 15 Chapters to deeply display the North America Wound Care Biologics market. Chapter 1, to describe Wound Care Biologics Introduction, product type and ...
May 2017
115 pages
Global Wound Care Biologics Market by Manufacturers, Countries, Type and Application, Forecast to 2022
US$ 3,480.00
... Acute Wounds Chronic Wounds Surgical Wounds There are 15 Chapters to deeply display the global Wound Care Biologics market. Chapter 1, to describe Wound Care Biologics Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of Wound Care Biologics, with ...
May 2017
115 pages
Brain Ischemia - Pipeline Review, H1 2017
US$ 2,000.00
... pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Brain Ischemia (Central Nervous System), complete with analysis by stage of development ...
May 2017
54 pages
Melasma (Chlosma) - Pipeline Review, H1 2017
US$ 2,000.00
... pipeline guide Melasma (Chlosma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melasma (Chlosma) (Dermatology), complete with analysis by stage of development ...
May 2017
27 pages
Adrenoleukodystrophy - Pipeline Review, H1 2017
US$ 2,000.00
... Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
May 2017
61 pages
End-Stage Kidney Disease - Pipeline Review, H1 2017
US$ 2,000.00
... key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed ...
May 2017
54 pages
Soluble Dietary Fibers Market by Source (Fruits & Vegetables, Nuts & Seeds, and Cereals & Grains), Type (Inulin, Polydextrose, Pectin, and Beta-glucan), Application (Functional Foods & Beverages, Pharmaceuticals), and Region - Global Forecast to 2022
US$ 3,390.00
... of 13.4%.” The global soluble dietary fibers market was valued at USD 1.52 billion in 2016 and is projected to reach a value of USD 3.23 billion by 2022, growing at a CAGR of 13.4%. The soluble dietary fibers market is driven ... involved in manufacturing soluble dietary fibers have been considered as restraining factors for the market. “Functional foods & beverages segment dominated the soluble dietary fibers market in 2016.” Fiber ingredients are ...
May 2017
132 pages
Global Tissue Banking Market Research and Analysis, 2015-2022
US$ 3,495.00
... government policies impacting the Global Tissue Banking Market Insights about market determinants which are stimulating the Global Tissue Banking Market. Detailed and extensive market segments with regional distribution ...
May 2017
-
China Breathing Machines Market by Manufacturers, Regions (Province), Type and Application, Forecast to 2022
US$ 4,480.00
... display the China Breathing Machines market. Chapter 1, to describe Breathing Machines Introduction, product type and application, market overview, market analysis by Region (province), market opportunities, market risk, market driving force; Chapter ...
May 2017
115 pages
China MRI Market by Manufacturers, Regions (Province), Type and Application, Forecast to 2022
US$ 4,480.00
... China MRI market. Chapter 1, to describe MRI Introduction, product type and application, market overview, market analysis by Region (province), market opportunities, market risk, market driving force; Chapter 2, to analyze the manufacturers of MRI ...
May 2017
116 pages
China Paclitaxel Market by Manufacturers, Regions (Province), Type and Application, Forecast to 2022
US$ 4,480.00
... China Paclitaxel market. Chapter 1, to describe Paclitaxel Introduction, product type and application, market overview, market analysis by Region (province), market opportunities, market risk, market driving force; Chapter 2, to analyze the manufacturers of Paclitaxel ...
May 2017
123 pages
North America Antibody Market by Manufacturers, Countries, Type and Application, Forecast to 2022
US$ 4,480.00
... Antibody Market Segment by Applications, can be divided into Hospital Medical research institutions Others There are 15 Chapters to deeply display the North America Antibody market. Chapter 1, to describe Antibody Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force; Chapter 2, to analyze the manufacturers of Antibody ...
May 2017
115 pages
